SHOULDER & ELBOW
COA-ACO2018: Ketotifen fumarate vs. placebo for joint contracture after elbow fracture/dislocation
152 patients with an elbow dislocation, distal humerus fracture or proximal radius fracture, with or without concomitant ulna fracture, were randomized to either oral ketotifen fumarate or lactose placebo. Patients were assessed at 12 weeks post-injury for elbow range of motion in flexion-extension, the Disabilities of the Arm Shoulder, and Hand (DASH) questionnaire, incidence of complications, and incidence of union. Overall, no significant differences between groups were noted for any of the assessed outcomes. When operatiely managed patients and nonoperatively managed patients were compared irrespective of group allocation, patients treated operatively demonstrated significantly greater reduction in elbow extension at 12 weeks.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
